Genzyme Launches Medication for Kidney Patients in the UK

Genzyme announced that Renvela (sevelamer carbonate) is being formally launched in the UK market this week.

Oxford, UK-based  Genzyme announced that Renvela (sevelamer carbonate), a medication for the control of serum (blood) phosphorus in patients with hyperphosphataemia in chronic kidney disease (CKD), is being formally launched in the UK market this week.

Genzyme’s Oxford site will play a key role in launching, supporting and making available to patients this important product across the UK. A team of thirty employees is directly involved in working on this product at the Oxford site.

Elevated serum phosphorus levels (hyperphosphataemia) are common in patients with advanced CKD and several clinical studies show that patients with higher phosphate levels die earlier than those with normal phosphate levels i, ii, iii. Therefore controlling levels of phosphate is very important.

Steve Higgins, Interim General Manager at Genzyme, Oxford, said: “At Oxford we are proud of the part we play in delivering highly effective therapies for patients with life-threa